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Abstract: Using a computational model of bone adaptation, we investigated the
long-term ability of bisphosphonates to minimize proximal bone loss that is
associated with stress shielding in the tibia after long-stemmed total knee
arthroplasty (TKA). When invoking bisphosphonate effects, the remodeling activity
was suppressed, and the resorption size was reduced. Compared with the untreated
simulation, bisphosphonate slowed the rate of bone loss after TKA (42% reduction
in bone loss at 1 year). Activating the drug 3 months before the surgery reversed
bone loss associated with the reduction in such activities as walking, but it did not
provide any substantial benefit in the long-term. Late bisphosphonate treatment did
not reverse the bone loss that occurred 3.5 years after TKA, although it preserved
3% of bone normally lost without treatment. Key words: stress shielding, TKA,
bisphosphonate, finite element analysis, press fit.

Implant failure in total joint arthroplasty may be
prevented when adequate fixation of the implant
components is achieved after surgery and when
this fixation is maintained over the long-term [1].
Although mechanically stiff stems with a large
diameter and extensive porous coating (which
facilitates bony ingrowth) provide the initial sta
bility and fixation, these attributes, when applied
to femoral prostheses in total hip arthroplasty
(THA), have been found to be associated with
more pronounced periprosthetic bone resorption
[2]. Moreover, this bone loss compromises long-

term fixation, and loosening of the prosthesis may
occur [3].
Bone loss after total joint arthroplasty occurs, in
part, because the relatively stiffer implants reduce
the physiological loading of the contiguous bone,
leading to disuse bone remodeling. The majority of
such bone loss typically occurs within the first
year after total joint arthroplasty and has been
observed by serial x-ray absorptiometry in the
proximal femur after THA [4-8]. Similar findings
have been observed after total knee arthroplasty
(TKA) in the distal femur [9-11] as well as in the
proximal tibia [12-15]. Through implant design
(eg, peg or stem), material selection (eg, cobalt
chrome alloy or titanium alloy), and fixation tech
nique (eg, press fit or cement), attempts have been
made to minimize this phenomenon. Although
such efforts have improved the longevity of total
joint arthroplasty, mechanical-related bone loss
(ie, stress shielding) has not been prevented, and
multiple revision surgeries are still an eventual
ity, especially for young patients (younger than
50 years) with a reconstructed joint who are

typically more active and live longer than older
patients with a joint arthroplasty.
It is well documented that the drug alendronate
increases bone mineral density (BMD) in the
femoral neck and trochanter of postmenopausal
women with osteoporosis [16-25]. This bisphosph
onate drug may be equally effective in preventing
or reversing bone loss associated with stress shield
ing. There is the possibility, however, that bisphos
phonates may disrupt the important process of
bone apposition to implant surfaces, which ensures
adequate fixation, because bisphosphonates can
inhibit mineralization (especially at high dosages).
Allaying such a concern, Frenkel et al [26] and
Mochida et al [27] found that alendronate did not
inhibit bony integration to various titanium sur
faces and hydroxyapatite-coated femoral stems,
respectively, in a dog model.
Whether bisphosphonates can prevent bone loss
associated with total joint arthroplasty as they do
for postmenopausal bone has been explored in
both animals and human beings. Besides stress
shielding, bone loss may result from the cellular
response (ie, macrophages) to wear debris. There
fore, using a rat model of particulate-induced
osteolysis, alendronate was studied and found to
prevent or reverse bone loss in the tibia [28] and
the femur [29] when polyethylene particles were
injected near the implant. Because there was more
bone around the implant in the group subjected to
particulates and alendronate, although osteoclasts
were present, than in the nontreated group (im
plant only), Millett et al [28] concluded that
alendronate reduces osteoclastic activity, thereby
reducing bone resorption and preserving bone.
Venesmaa et al [30] and Soininvaara et al [31]
investigated whether alendronate could prevent
periprosthetic bone loss in the human femur after
THA and TKA, respectively. Each prospective
randomized trial found that the alendronate
treated group had a significantly smaller decrease
in BMD than the calcium only–treated group after
6 months to 1 year of total joint arthroplasty.
Similarly, Wilkinson et al [32] found that a single
dose of another bisphosphonate drug, pamidronate,
significantly reduced proximal bone loss in the
femur by 26 weeks after THA compared with a
control. Moreover, the drug was not associated with
more adverse events (eg, cardiac failure and diar
rhea) than normally occur after THA without
bisphosphonate treatment.
Although these studies suggest that bisphospho
nates can reduce bone loss after total joint arthro
plasty, the question still remains whether this effect
can be maintained over the long term. To investi

gate this in a relatively short time frame, bisphosph
onate effects were simulated here with existing
computational models of bone remodeling devel
oped for the tibia with long-stemmed TKA [33] and
for bisphosphonate treatment [34]. Additional
questions that were investigated with this theoret
ical model were (1) would bisphosphonates given
3 months before surgery provide better protection
against bone loss than those given immediately
after surgery? (2) do bisphosphonates recover bone
that has already been lost to stress shielding? and
(3) what are the relative contributions of suppres
sion of remodeling activity and reduction in resorp
tion area to minimizing bone loss?

Materials and Methods
Bone Adaptation Model
Changes in bone mass after long-stemmed TKA
with and without bisphosphonate treatment were
simulated using a finite element model of the tibia
coupled with a theoretical model of bone remodel
ing [33]. In the theoretical model, which is des
cribed by Hazelwood et al [35], bone loss associated
with disuse was assumed to occur when a me
chanical stimulus (U) dropped below a disuse
threshold (U 0). In each element of bone, the
mechanical stimulus was estimated from the prin
cipal strains (e) of 3 daily loading activities and
their respective loading frequency (R L):
U¼

3
X

e4 RLi

ð1Þ

i¼1

When the mechanical stimulus is less than the
disuse threshold, the activation frequency (Ac.f) of
basic multicellular units (BMUs), the teams of cells
that remove and then replenish packets of bone,
were increased in both cortical and trabecular
bone. The disuse-related increase in remodeling
activity resulted in bone loss caused by an increase
in the number of resorption sites. Also, if the
porosity was greater than 20% and the bone was in
a state of disuse, bone formation decreased relative
to resorption in each BMU, thereby causing
negative bone turnover or disuse remodeling:


U
Formation ¼ 0:5 � Resorption 1 þ
U0

ð2Þ

In other words, the bone balance ratio (forma
tion per resorption) at the BMU level was less than
1 when bone was in state of disuse. The model
tracked changes in the amount of bone occupying a
representative area within each element via the
history of activation frequency as BMUs progress

From the equilibrium, normal condition, the
forces and loading frequencies acting on the model
were reduced by 10% and 22%, respectively, to
simulate loss of loading activity caused by osteoar
thritic pain [37]. Bone remodeling was then
allowed to evolve for another 200 days. We did
not include any aging or disease effects on the
material behavior of bone (ie, the relationship
between BAF and modulus did not change).
A long-stem version of TKA was selected so that
the effectiveness of bisphosphonate in preserving
bone mass would be investigated in a severe case of
stress shielding. We set the TKA components,
comprised of a 16 � 120 mm press fit, titanium
alloy stem with a cemented tibial tray, and ultra
high molecular weight polyethylene insert, to their
respective material properties (Table 1) and ran
implant simulations for the succeeding 6.5 years
without bisphosphonate treatment or with treat
ment starting on either the day of TKA, 3 months
before TKA, or 3.5 years after TKA. Joint reaction
forces, but not loading frequency, were returned to
normal after 100 days. Bone loss was quantified
below the tibial tray as percent change from the
intact tibial BAF after reduction in loading activity.
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Fig. 1. Comparing distribution of BAF in the nonoper
ated tibial bone at steady state (A) to that for TKA at 700
days postoperative TKA reveals a greater loss of bone
when bisphosphonates are not simulated (B) than when
their effects are included immediately postoperative (C).

through the resorption, reversal, and formation
periods. Bone mass was thus calculated as bone
area per total area or bone area fraction (BAF).
Bone Remodeling Simulations
Starting with a homogeneous material state
throughout the tibia and applying physiological
joint reaction forces, the bone mass distribution
was allowed to evolve until each variable of the
model reached a steady state as described in a
previous study [33]. Briefly, the joint reaction force
was evenly distributed normal to each condyle
surface in 1 situation, and then the other situations
had medial-biased (70%/30%) or lateral-biased
(30%/70%) loading with a 58 tilt to account for
lateral or medial ground reaction forces. The model
calculated tibial surface strains in the physiological
range, as measured by Burr et al [36]. Once a
steady state was achieved, the tibia model exhibited
a normal anatomic distribution of cortical and
cancellous bone that was used as the starting point
for the current study (Fig. 1A).

Bisphosphonate Effects
The 2 main antiresorptive actions of bisphosph
onate are the inhibition of BMU activation fre
quency and reduction in erosion by the BMU [40].
Because these actions occur when the bisphosph
onate comes in contact with an osteoclast and
suppression is greatest in regions of high remodel
ing activity [41], the potency of suppressing
activation frequency was a function of the number
of resorbing BMUs.


P ¼ Pmax 1 � e�ss �N :Rs:BM U

ð3Þ

where P max is the maximum suppression coeffi
cient, s s is the rate of suppression coefficient, and
N.Rs.BMU is the number of resorbing BMUs.
Bisphosphonate treatment was simulated in the

Table 1. Material Properties for the Components of TKA and for Bone
Material
PMMA
UHMWPE
Titanium
Cortical
Trabecular

Young’s modulus (MPa)

Poisson’s ratio

Location

Reference

2150
2300
79 000
23 400 (BAF)5.74
14 300 (BAF)1.33

0.46
0.25
0.36
0.30
0.30

Below tray
Tibial insert
Tray and stem
BAF N0.8; Fig. 2A
BAF V0.8; Fig. 2A

Lewis et al [38]
Lewis et al [38]
Lewis et al [38]
Turner et al [39]
Turner et al [39]

Abbreviation: UHMWPE, ultrahigh molecular weight polyethylene.

model by suppressing BMU activation frequency by
the percentage of P, and then independent of
activation frequency suppression, the normal re
sorption by BMUs was reduced by 3/13th,
corresponding to the reduction in erosion depth
observed by Chavassieux et al [42]. In a previous
study by Nyman et al [34], these antiresorptive
actions were invoked in a representative volume of
postmenopausal trabecular bone. With a maximum
suppression coefficient of 1.0, a rate of suppression
coefficient of 5, and a reduction in the erosion
depth by 3/13th, the simulation predicted an
increase in bone mass similar to that observed by
dual-energy x-ray absorptiometry over 7 years in
the spines of postmenopausal women who were
treated daily with 10 mg of alendronate [24]. More
specifically, the simulation matched the clinically
observed 4% increase in BMD over the first
6 months of treatment. It also matched the
decreasing rate of BMD increase between 6 months
and 7 years of treatment. Therefore, these coef
ficients were invoked when simulating bisphosph
onate effects in the TKA model.
In 2 additional simulations of bisphosphonate
treatment starting on the day of TKA, (a) the rate of
suppression coefficient was increased to 20 without
changing the reduction in resorption and (b)
resorption was reduced by 2/7th without changing
the rate of suppression. The former action effec
tively increases the suppression of activation fre
quency of new BMUs, whereas the latter further
reduces the size of resorption space created by
BMUs. This sensitivity analysis was done to inves
tigate the contributions of activation suppression
and bone balance, respectively, on inhibiting bone
loss associated with stress shielding (ie, mechani
cally induced disuse bone remodeling). To eluci
date the underlying mechanism of bone loss in the
model, mechanical stimulus, activation frequency,
and bone balance were recorded (as an average
within the region of interest) over time for
each simulation.

Results
Compared with the untreated simulation,
bisphosphonate treatment preserved bone mass
after TKA (Fig. 2). Furthermore, it prevented the
thinning of the cortices that can occur with TKA. Its
antiresorptive effects, however, did not completely
prevent proximal bone loss associated with stress
shielding but slowed the progression of loss (Fig. 2).
One year after TKA, there was an average of 42.0%
less bone loss below the tibial tray with bisphosph-

Fig. 2. The rate of bone loss after TKA below the
tibial tray is slower when bisphosphonate effects are
simulated than without treatment. Abbreviation: BP,
bisphosphonate.

onate treatment given the day of surgery than
without bisphosphonate treatment. Activating the
drug 3 months before TKA reversed some of the
bone loss associated with the reduction in loading
activity that typically occurs with osteoarthritic
knees, but it did not provide any substantial benefit
in the long term. Bisphosphonate given 3.5 years
after TKA did not reverse the bone loss that
occurred up to that time after surgery, although it
slowed the rate of loss (saved 3% of bone normally
lost at 6.5 years). Increasing activation frequency
suppression potency of a bisphosphonate drug had
a greater effect than reducing the resorption size
(ie, improving the bone balance) in preserving
bone over the long term.
Decreasing the loading activity lowered the
mechanical stimulus below the disuse threshold
and subsequently caused bone loss (Fig. 2). Reduc
ing bone resorption by invoking bisphosphonate
treatment before TKA caused positive bone turn
over within the BMU (ie, more bone was added
than removed as shown in Fig. 3), and bone loss
was temporarily reversed (dotted line in Fig. 2).
When the long-stemmed TKA was simulated at 6
months after reduction in loading, bone loss in the
model resumed, despite the pharmacological sup
pression of bone resorption and the return of
normal joint reaction forces. In the model of
long-stem TKA without drug intervention, signifi
cant stress shielding had 2 consequences: (a)
increased remodeling activity introduced porosity
and (b) bone formation in each BMU decreased
relative to resorption. This elevated rate of remod
eling subsided over time as the reduction of bone

Fig. 3. Bone balance, the ratio of formation area (FAr)
to resorption area (Rs.Ar) is less than 1 because the state
of disuse caused by the TKA overrides the increase
provided by bisphosphonate unless the drug is given
3.5 years postoperatively.

mass increased the strain. With bisphosphonate
treatment, the stimulation of disuse remodeling by
TKA was suppressed. However, there was still a
decrease in bone formation, and although the drug
decreased BMU erosion depth, formation remained
less than resorption (Fig. 3). In other words, the
drug did not overcome the consequences of stress
shielding but delayed them.

Discussion
The objective of simulating the antiresorptive
action of bisphosphonate in a hypothetical bone
adaptation model of long-stem TKA was to inves
tigate (1) whether the drug minimizes bone loss
associated with stress shielding over the long term,
(2) whether giving the drug in advance of surgery
provided any additional benefit, and (3) whether
the drug could recover bone mass that had already
been lost because of stress shielding. Secondary
objectives included investigating the relative con
tributions of activation frequency suppression and
resorption size reduction in minimizing bone loss
and understanding the underlying mechanisms of
bone loss.
Bisphosphonate treatment in the present study
minimized bone loss after TKA, reducing bone loss
by almost one half below the tibial tray during the
6.5-year period. Bone loss was not completely
stopped because (a) remodeling was suppressed
but not completely blocked and (b) a disuse state
or stress shielding was prolonged compared with

TKA without treatment. To clarify, without antiresorptive action, bone strains increased after their
initial decrease as bone stiffness was lost to stress
shielding. Subsequently, the mechanical stimulus
returned to the threshold level, and the bone
balance approached one (Fig. 3) as the rate of
bone loss slowed. With bisphosphonate treatment,
however, the preservation of bone kept the strain
on bone at a reduced level. Therefore, despite the
reduction in bone resorption relative to normal
bone formation, the disuse state imposed a nega
tive bone turnover (ie, resorption was greater
than formation).
Despite an improvement in the bone balance
ratio (ie, increased positive bone turnover per
BMU) when bisphosphonate treatment was given
3.5 years after TKA, there was no significant gain in
bone. This was because of the rather low remodel
ing activity occurring at the time of treatment.
There were too few BMUs to cause perceptible
increase in bone mass. For a gain to occur, a
pharmacological agent would likely need to pro
mote bone formation in addition to suppressing
bone resorption.
In the present model, invoking a more sensitive
suppression of remodeling activity (a rate of
suppression coefficient of 20 instead of 5) caused
fewer number of resorbing BMUs, whereas invok
ing a greater reduction in resorption by osteoclasts
(71.4% of normal formation instead of 76.9% of
normal formation) caused a more positive bone
turnover per BMU. Interestingly, the model pre
dicted that increasing the potency of a bisphosph
onate drug further reduces the amount of bone
formed at the BMU level (compare the dotted line
to the triangle line in Fig. 3) but still reduces the
amount of bone loss overall. This was because of
the fact that there were fewer BMUs to remove
bone with high suppression. Based on the predic
tions of the present bone remodeling simulations,
greater potency of remodeling suppression should
be a higher priority than greater potency of
resorption reduction when designing bisphospho
nate drugs for TKA.
To the best of our knowledge, the effect of
bisphosphonates on tibial bone density after TKA
has not been studied. Moreover, there are no
clinical studies that have measured bone loss below
the tibial tray for long-stemmed TKA. Nonetheless,
there are 3 clinical observations that support the
suitability of the present analytical model. First,
several studies observed that the majority of bone
loss in the tibia after TKA occurs in the first year
and diminishes thereafter [12,14,15,43]. This trend
was predicted by the model when simulating TKA

without bisphosphonate treatment (Fig. 2). Sec
ond, the predicted thinning of the cortices by the
model (Fig. 1B) has been observed clinically after
TKA by Seitz et al [44]. Third, Karbowski et al [12]
reported that a tibial endoprosthesis with stem
length of 40 mm caused an average 9.26% decrease
in tibial bone density below the tray after 9 months
of TKA, and Regner et al [15] reported a tibial
endoprosthesis with stem length of 60 mm that
caused an average 22% decrease in tibial bone
density in a similar region. From a mechanical
viewpoint, bone loss increases with an increase in
stem length [45]. Thus, a greater bone loss than
found clinically for shorter stems would occur for a
120-mm stem as the model predicts. Lastly, bone
loss did occur in the short term after THA or
TKA when patients were given bisphosphonates
[30-32], and it was significantly less than in
patients who were not treated with the drug.
The model also predicted much less bone loss for
treated TKA compared with TKAs without the
actions of bisphosphonate.
The present findings come from a hypothetical
model of TKA bone adaptation, so they should
be interpreted in light of the limitations of the
model. Such limitations included those related to
2-dimensional finite element models: plane strain
assumptions, exclusion of out-of-plane forces, sim
plification of geometry, and idealization of material
behavior. Nonetheless, the model predicts the
morphological characteristics of the tibia (cortices
at the diaphysis, medullary canal, and cancellous
bone in metaphysis) given the few hypothetical
loading activities. One limitation in the simulation
of bisphosphonate treatment is the absence of the
contribution of secondary mineralization to bone
mass. Because bisphosphonates slow remodeling
activity, there is more time for bone to mineralize,
which increases mass, before being replaced with
fresh osteoid [46]. This is an additive effect suggest
ing that the present study overpredicts bone loss
with the drug. Another possible limitation is the
independence between the fixed reduction in
resorption size and suppression of remodeling
activity. Unlike activation frequency suppression,
resorption reduction was not a function of the
number of resorbing BMUs (ie, as the presence of
osteoclasts increased, the resorbing efficiency or
BMU life span did not decrease proportionally). The
consequence of this is unclear because resorption
size affects both porosity (hence, stiffness of bone)
and microdamage removal (hence, the demand for
activation frequency).
The results of the present study suggest that
bisphosphonate treatment starting on the day of

TKA may slow the progression of bone loss
associated with stress shielding. Preserving bone
mass over the long term would reduce the likeli
hood of aseptic loosening, a common cause for
revision. There appears to be no advantage of
giving the drug in advance to prevent bone loss
because of a reduction in loading activity, and
starting the administration of the drug several years
after surgery may only provide modest benefits.
Because of known side effects and a long half-life
(N10 years), routine use of bisphosphonate in TKA
would require a long-term clinical study.
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